The clinical observation of pediatric antibiotic associated diarrhea prevented and treated by bifidobacterium lactobacillus triple living bacterium tablet
10.3760/cma.j.issn.1008-6706.2014.06.013
- VernacularTitle:双歧杆菌乳杆菌三联活菌防治小儿抗生素相关性腹泻的临床观察
- Author:
Liyan YIN
- Publication Type:Journal Article
- Keywords:
Diarrhea;
Bifidobacterium lactobacillus triple living bacterium tablet;
Child
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;21(6):829-831
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of bifidobacterium lactobacillus triple living bacterium tablet in the prevention and treatment of pediatric antibiotic associated diarrhea(AAD).Methods 300 children with respiratory tract infection were selected,firstly they were divided into group A(1 month-lyear old) 140 cases and group B(1-3years old) 160 cases according to the age;secondly,they were randomly divided into observation group (group A:70 cases and group B:80 cases) and control group 150 cases (group A:70 cases and group B:80 cases)within the A,B groups.Control group was given antibiotics to treat respiratory tract infection,and received conventional treatment after diarrhea appeared.Observation group was given bifidobacterium lactobacillus triple living bacterium tablet combined with antibiotics,continued to receive this drug on the basis of conventional treatment after diarrhea appeared.The incidence rate of diarrhea,total effective rate,duration of diarrhea were observed.Results The incidence rate of diarrhea of observation group was obviously lower than the control group,diarrhea treatment overall effective rate obviously higher than control group,the duration of diarrhea significantly shorter than the control group,with significant difference(P ＜ 0.05) ;The incidence rate of diarrhea of observation group in group B was obviously lower than the observation group in group A,with significant difference (P ＜ 0.05).Conclusion The clinical effect of bifidobacterium lactobacillus triple living bacterium tablet in the prevention and treatment of pediatric AAD is significant,especially for 1-3 years old children,it is worth clinical promotion.
